GlassScriptPhysician profile
Sarah Singer Rivera
NPI 1326366998
$2,355.48
in general payments reported to CMS, 2019-2025
28 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $300 · 2021: $273 · 2022: $558 · 2023: $387 · 2024: $366 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.84 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $478.73 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $245.59 | 2020-2023 | Lo Loestrin Fe |
| Organon LLC | $175.03 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $152.45 | 2019-2022 | |
| Sage Therapeutics, LLC | $122.46 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $114.45 | 2021-2022 | |
| Hologic Sales and Service, LLC | $114.00 | 2020-2022 | |
| Avion Pharmaceuticals | $113.73 | 2020-2022 | |
| Amgen INC. | $90.95 | 2019-2020 | |
| Renovia INC | $87.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.01 | 2021-2025 | |
| Ethicon US, LLC | $76.87 | 2024-2025 | Enseal X1, Ethicon, Stratafix |
| Coopersurgical, INC. | $68.52 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Aspira Women'S Health INC | $59.21 | 2019-2022 | |
| Exeltis, USA INC. | $54.90 | 2021-2025 | Slynd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $49.88 | 2022 | |
| Mylan Pharmaceuticals INC. | $38.43 | 2022 | |
| Allergan, INC. | $36.46 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $26.81 | 2024 | Myfembree |
| Daiichi Sankyo INC. | $24.63 | 2022 | |
| Heron Therapeutics, INC. | $22.96 | 2023 | Zynrelef |
| Scynexis, INC. | $22.24 | 2022 | |
| Myovant Sciences INC. | $19.88 | 2021 | |
| Amag Pharmaceuticals, INC. | $16.47 | 2019 | |
| Merck Sharp & Dohme LLC | $16.29 | 2024 | Gardasil, Gardasil 9 |
| Medtronic, INC. | $16.24 | 2024 | Ligasure |
| Minerva Surgical, INC | $12.48 | 2022 | |
| Duchesnay USA Incorporated | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.